RSCM
PHAS
Rock Springs Capital Management’s PhaseBio Pharmaceuticals, Inc. Common Stock PHAS Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-2,719,074
| Closed | -$479K | – | 126 |
|
|
2022
Q3 | $479K | Sell |
2,719,074
-55,795
| -2% | -$9.83K | 0.01% | 125 |
|
|
2022
Q2 | $1.67M | Buy |
2,774,869
+161,044
| +6% | +$96.6K | 0.05% | 117 |
|
|
2022
Q1 | $3.45M | Buy |
2,613,825
+32,526
| +1% | +$42.9K | 0.09% | 112 |
|
|
2021
Q4 | $6.74M | Buy |
2,581,299
+737,535
| +40% | +$1.92M | 0.16% | 108 |
|
|
2021
Q3 | $5.73M | Hold |
1,843,764
| – | – | 0.12% | 124 |
|
|
2021
Q2 | $6.86M | Buy |
1,843,764
+289,790
| +19% | +$1.08M | 0.14% | 127 |
|
|
2021
Q1 | $5.38M | Buy |
1,553,974
+239,600
| +18% | +$829K | 0.12% | 131 |
|
|
2020
Q4 | $4.42M | Buy |
1,314,374
+1,200
| +0.1% | +$4.03K | 0.09% | 138 |
|
|
2020
Q3 | $4.61M | Buy |
1,313,174
+169,249
| +15% | +$594K | 0.12% | 131 |
|
|
2020
Q2 | $5.26M | Buy |
1,143,925
+18,925
| +2% | +$87.1K | 0.14% | 129 |
|
|
2020
Q1 | $3.72M | Hold |
1,125,000
| – | – | 0.15% | 111 |
|
|
2019
Q4 | $6.87M | Sell |
1,125,000
-291,900
| -21% | -$1.78M | 0.22% | 97 |
|
|
2019
Q3 | $5.91M | Sell |
1,416,900
-6,356
| -0.4% | -$26.5K | 0.24% | 96 |
|
|
2019
Q2 | $18.7M | Buy |
1,423,256
+283,256
| +25% | +$3.72M | 0.68% | 53 |
|
|
2019
Q1 | $10.8M | Buy |
1,140,000
+305,000
| +37% | +$2.9M | 0.42% | 74 |
|
|
2018
Q4 | $2.58M | Buy |
+835,000
| New | +$2.58M | 0.12% | 118 |
|